Verrica Pharmaceuticals reports Q4 loss, misses revenue estimates, stock declined by 9%

From Nasdaq: 2025-03-11 17:25:05

Verrica Pharmaceuticals Inc. (VRCA) reported a quarterly loss of $0.24 per share, beating the Zacks Consensus Estimate of $0.25. This marks a significant improvement from the $0.48 loss per share reported a year ago. The company has surpassed EPS estimates three out of the last four quarters.

However, Verrica Pharmaceuticals fell short on revenue, reporting $0.34 million for the quarter, missing the Zacks Consensus Estimate by 80.78%. The stock has declined by 9% since the start of the year, underperforming the market.

Investors are now waiting to see how the stock will perform in the future. The company’s earnings outlook and estimate revisions will play a crucial role in determining its trajectory. The current Zacks Rank for Verrica Pharmaceuticals is #3 (Hold), indicating a neutral outlook for the stock.

Another company in the same industry, Century Therapeutics, Inc. (IPSC), is expected to report a quarterly loss of $0.45 per share, with revenues projected to be $38.15 million, a significant increase from the year-ago quarter.

For investors considering Verrica Pharmaceuticals, it’s important to stay informed about the company’s future performance and industry outlook. Monitoring earnings estimates and industry rankings can provide valuable insights for making investment decisions in the pharmaceutical sector.



Read more at Nasdaq: Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates